SITC 2021 | ARTACUS: exploring the RP1 oncolytic virus for the treatment of cancer patients with CSCC

Jason Luke, MD, FACP, UPMC Hillman Cancer Center, Pittsburgh, PA, outlines the Phase I ARTACUS (NCT04349436) trial in patients with cutaneous squamous cell carcinoma (CSCC). The ongoing Phase I trial investigates the RP1 oncolytic virus for the treatment of patients who have developed CSCC due to the suppression of their immune system following a solid organ transplant. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.